MétaCan
Menu
Back to cohort
Record W4385683760 · doi:10.1177/13524585231189671

Improving the efficiency of clinical trials in multiple sclerosis

2023· review· en· W4385683760 on OpenAlexaff
Ruth Ann Marrie, Maria Pia Sormani, Sean Apap Mangion, Francesca Bovis, Winson Y. Cheung, Gary Cutter, Peter Feys, Michael D. Hill, Marcus Koch, Morgan McCreary, Ellen M. Mowry, Jay Park, Fredrik Piehl, Amber Salter, Jeremy Chataway

Bibliographic record

VenueMultiple Sclerosis Journal · 2023
Typereview
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsMcMaster UniversityImpactUniversity of CalgaryUniversity of Manitoba
FundersSanofi GenzymeChugai PharmaceuticalEMD SeronoNational Institutes of HealthUniversity College LondonGenentechMultiple Sclerosis SocietyEuropean Committee for Treatment and Research in Multiple SclerosisTeva Pharmaceutical IndustriesNational Institute for Health and Care ResearchRegeneron PharmaceuticalsH. Lundbeck A/SPatient-Centered Outcomes Research InstituteMedical Research CouncilBiogenMerck KGaAUniversity College London Hospitals NHS Foundation TrustRosetrees TrustU.S. Department of DefenseSanofiNational Multiple Sclerosis Society
KeywordsClinical trialMultiple sclerosisMedicineClinical study designSample size determinationPathology

Abstract

fetched live from OpenAlex

BACKGROUND: Phase 3 clinical trials for disease-modifying therapies in relapsing-remitting multiple sclerosis (RRMS) have utilized a limited number of conventional designs with a high degree of success. However, these designs limit the types of questions that can be addressed, and the time and cost required. Moreover, trials involving people with progressive multiple sclerosis (MS) have been less successful. OBJECTIVE: The objective of this paper is to discuss complex innovative trial designs, intermediate and composite outcomes and to improve the efficiency of trial design in MS and broaden questions that can be addressed, particularly as applied to progressive MS. METHODS: We held an international workshop with experts in clinical trial design. RESULTS: Recommendations include increasing the use of complex innovative designs, developing biomarkers to enrich progressive MS trial populations, prioritize intermediate outcomes for further development that target therapeutic mechanisms of action other than peripherally mediated inflammation, investigate acceptability to people with MS of data linkage for studying long-term outcomes of clinical trials, use Bayesian designs to potentially reduce sample sizes required for pediatric trials, and provide sustained funding for platform trials and registries that can support pragmatic trials. CONCLUSION: Novel trial designs and further development of intermediate outcomes may improve clinical trial efficiency in MS and address novel therapeutic questions.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.066
metaresearch head score (Gemma)0.192
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow), Research integrity
Consensus categoriesMetaresearch, Meta-epidemiology (narrow)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.973
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0660.192
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0140.007
Bibliometrics0.0020.003
Science and technology studies0.0010.001
Scholarly communication0.0000.000
Open science0.0020.001
Research integrity0.0010.006
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.715
GPT teacher head0.505
Teacher spread0.210 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designOther design
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations19
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueMultiple Sclerosis JournalSame topicMultiple Sclerosis Research StudiesFrench-language works237,207